IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/WF1 mice

Clinical and Experimental Immunology

Volumn 112, Issue 3, 1998, Pages 397-402

  Mihara, M ^a   Takagi, N ^a   Takeda, Y ^a   Ohsugi, Y ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti IL 6R antibody; Autoimmune kidney disease; NZB WF1 mice

Indexed keywords

COMPLEMENT COMPONENT C3; DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNODIFFUSION; IMMUNOLOGICAL TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; FEMALE; IMMUNOGLOBULIN G; INTERLEUKIN-6; KIDNEY DISEASES; MICE; RECEPTORS, INTERLEUKIN-6;

EID: 0031861643     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00612.x     Document Type: Article

References (29)

1. Linker-Israeli M, Deans RJ, Wallace DJ et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147:117-23.
2. Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18:1797-801.
3. Hirano T, Taga T, Yasukawa K et al. Human B cell differentiation factor defined by a anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987; 84:228-31.
4. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360-7.
5. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37:269-388.
6. Tang B, Matsuda T, Akira S et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991; 3:273-8.
7. Mihara M, Fukui H, Koishihara Y et al. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol 1990; 82:533-7.
8. Mihara M, Ohsugi Y. Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W F1 mice: induction of IgG class anti-DNA autoantibody production. Int Arch Allergy Appl Immunol 1990; 93:89-92.
9. Alarcon-Riquelme ME, Moller G, Fernandez C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB X NZW) F1 hybrid. Clin Immunol Immunopathol 1992; 62:264-9.
10. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90:11924-8.
11. Fujita J, Tsujinaka T, Yano M et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996; 68:637-43.
12. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994; 94:585-91.
13. Mihara M, Nakano T, Ohsugi Y. An immunomodulating antirheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice. Clin Immunol Immunopathol 1987; 45:366-74.
14. Mihara M, Ohsugi Y. Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation. Clin Exp Immunol 1989; 78:102-7.
15. Steward MW, Hay FC. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in NZB/W F1 hybrid mice. Clin Exp Immunol 1976; 26:363-70.
16. Mihara M, Ohsugi Y, Saito K et al. Immunologic abnormality in NZB/ NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. J Immunol 1988; 141:85-90.
17. Muraguchi A, Hiranao T, Tang B et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-44.
18. Beagley KW, Eldrige JH, Lee F et al. Interleukins and IgA synthesis: human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 1989; 169:2133-48.
19. Vercelli D, Jabara HH, Arai K et al. Endogenous interleukin-6 plays an obligatory role in interleukin-4 dependent human IgE synthesis. Eur J Immunol 1989; 19:1419-24.
20. Kopf M, Baumann H, Freer G et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-42.
21. Bromander AK, Ekman L, Kopf M et al. IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J Immunol 1996; 156:4290-7.
22. Gutstein NL, Seaman WE, Scott JH et al. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol 1986; 137:1127-32.
23. Heremans H, Dillen C, Put W et al. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 1992; 22:2395-401.
24. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20:259-62.
25. Schindler R, Mancilla J, Endres S et al. Correlations and interactions in the production of interleukin-6 (IL-6). IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75:40-47.
26. Tilg H, Trehu E, Atkins MB et al. Interleukin-6 (IL-6) as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-8.
27. Izui S, Fernandes G, Hara I et al. Low-calorie diet selectively reduces expression of retroviral envelope glycoprotein gp70 in sera of NZBxNZW F1 hybrid mice. J Exp Med 1981; 154:1116-24.
28. Falus A, Rokita H, Walcz E et al. Hormonal regulation of complement biosynthesis in human cell lines. II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990; 27:197-201.
29. Katz Y, Revel M, Strunk RC. Interleukin 6 stimulates synthesis of complement protein factor B and C3 in human skin fibroblast. Eur J Immunol 1989; 19:983-8.